Amedeo Smart

Free Medical Literature Service


 

Amedeo

Inflammatory Bowel Diseases

  Free Subscription

Articles published in
JAMA
    February 2024
  1. VOELKER R
    What Is Ulcerative Colitis?
    JAMA. 2024 Feb 2. doi: 10.1001/jama.2023.23814.
    >> Share

    November 2023
  2. SURAN M
    Highlights From Gastroenterology Week: New Crohn Disease Drug, Redefining Liver Disease, and More.
    JAMA. 2023 Nov 2. doi: 10.1001/jama.2023.19140.
    >> Share

    September 2023
  3. GROS B, Kaplan GG
    Ulcerative Colitis in Adults: A Review.
    JAMA. 2023;330:951-965.
    >> Share

    March 2023
  4. HARRIS E
    Patients With Normal Gut Biopsy Still at Increased Risk of IBD.
    JAMA. 2023;329:875.
    >> Share

  5. ZHANG S, Chen B, Wang B, Chen H, et al
    Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial.
    JAMA. 2023;329:725-734.
    >> Share

    April 2022
  6. VANDE CASTEELE N
    Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    JAMA. 2022;327:1506.
    >> Share

  7. JAVOR E, Hauser G, Skelin M
    Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    JAMA. 2022;327:1505-1506.
    >> Share

  8. SYVERSEN SW, Jahnsen J, Haavardsholm EA
    Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply.
    JAMA. 2022;327:1506-1507.
    >> Share

    December 2021
  9. SYVERSEN SW, Jorgensen KK, Goll GL, Brun MK, et al
    Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    JAMA. 2021;326:2375-2384.
    >> Share

    October 2021
  10. ABBASI J
    Vaccine-Induced SARS-CoV-2 Antibodies in Inflammatory Diseases.
    JAMA. 2021;326:1365.
    >> Share

    September 2021
  11. SERKLAND TT, Skrede S, Berg JA
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;326:1068-1069.
    >> Share

  12. LE TILLY O, Paintaud G, Ternant D
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;326:1069.
    >> Share

  13. PAPAMICHAIL K, Dubinsky MC, Cheifetz AS
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;326:1067-1068.
    >> Share

  14. SYVERSEN SW, Bolstad N, Haavardsholm EA
    Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
    JAMA. 2021;326:1069-1070.
    >> Share

    July 2021
  15. SLOMSKI A
    Filgotinib Induces and Maintains Ulcerative Colitis Remission.
    JAMA. 2021;326:299.
    >> Share

    May 2021
  16. BAYOUMY AB, de Boer NKH, Mulder CJJ
    Management of Crohn Disease.
    JAMA. 2021;325:1793-1794.
    >> Share

  17. CUSHING K, Higgins PDR
    Management of Crohn Disease-Reply.
    JAMA. 2021;325:1794-1795.
    >> Share

  18. CURTIS JR, Ogdie A, George MD
    Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases.
    JAMA. 2021;325:1726-1728.
    >> Share

  19. SYVERSEN SW, Goll GL, Jorgensen KK, Sandanger O, et al
    Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    JAMA. 2021;325:1744-1754.
    >> Share

    January 2021
  20. CUSHING K, Higgins PDR
    Management of Crohn Disease: A Review.
    JAMA. 2021;325:69-80.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016